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Abstract
 
Research has documented the drastic reduction of unintentional 
poisonings of children since the introduction of child resistant (CR) 
packaging. However, studies also indicate that consumers report 
diﬃculty using CR packages, in part because tests which determine 
the 'senior friendliness' of CR designs that are used throughout the 
world disallow people with 'overt or obvious' disabilities from being 
test subjects. Our review of drug package usability suggests that the 
current tests of CR packaging can and should be revised to correct 
this problem. We use US legislation, regulation and data to 
exemplify these points, but the conclusions are applicable to all 
protocols that include the exclusionary provision. 
Introduction 
The testing protocols for senior friendly ⁄ child 
resistant (CR) packaging frequently exclude 
people with 'overt or obvious disabilities' and 
those who are unable to follow written direc­
tions (people with visual impairments and illit­
erate subjects) as eligible test subjects. These 
exclusionary practices do not adequately honour 
the ethical principle of justice. 
A review of the evolution of protocol testing 
for senior friendly ⁄CR packaging is presented. 
This is followed by a discussion of ethical prin­
ciples that should undergird research involving 
human subjects and problems the exclusionary 
practice presents, when viewed through this 
standard. Finally, we recommend changes to the 
protocol that would make it more objective and 
more inclusive. Although US documents are 
used to exemplify the ideas proposed, the 
implication exists wherever the exclusionary 
clause is present. 
History 
The unintentional poisoning of children as a 
result of the ingestion of household products 
became a noted problem shortly after the 
introduction of ﬂavoured aspirin in 1943. By 
1953, the ﬁrst US Poison Control Center had 
been established to serve as a central source of 
information and treatment. This was followed 
by the establishment of a US Clearinghouse for 
Poison Control Centers in 1957. The Clearing­
house was started to coordinate the eﬀorts of 
local centers, gather statistical data on poison­
ings, and provide diagnostic and therapeutic 
information. 
During this same year (1957) the over-the­
counter (OTC) drug industry voluntarily 
430 © 2009 The Authors. Journal compilation © 2009 Blackwell Publishing Ltd Health Expectations, 12, pp.430–437 
Is the test of senior friendly ⁄ CR packaging ethical?, L Bix et al. 431 
accepted the recommendations of a medical 
advisory panela to reduce the strength of chil­
dren's aspirin and to limit the number of tablets 
per package.1 Eﬀorts to develop 'safety closures' 
were also recommended by the panel at this 
time. 
Taking the suggestion of the medical advisory 
group, in 1959, researchers from Durham, NC 
(US) reiterated the need to use 'safety closures' 
for aspirin in an article that appeared in the 
Journal of the American Medical Association 
(JAMA).2 Ten years of hearings, debates, dis­
cussion and testing ensued until 1970, when the 
Congress enacted the Poison Prevention Pack­
aging Act of 1970 (PPPA), the ﬁrst act of its 
kind. 
The Act required 'special packaging' [child 
resistant (CR) packaging] on select drugs and 
household chemicals. The Act deﬁnes special 
packaging as, 'packaging that is designed or 
constructed to be signiﬁcantly diﬃcult for chil­
dren under 5 years of age to open or obtain a 
toxic or harmful amount of the substance con­
tained therein within a reasonable time and not 
diﬃcult for ''normal adults'' to use properly, but 
does not mean packaging which all such children 
cannot open or obtain a toxic or harmful 
amount within a reasonable time.'3 
Administration of the PPPA was the responsi­
bility of the Food and Drug Administration 
(FDA) until October, 1972, when public law 92– 
573 transferred administrative responsibility to 
the Consumer Product Safety Commission 
(CPSC)4 (see Table 1). The CPSC remains 
responsible for the regulation of the CR packag­
ing of drugs and household chemicals. Addi­
tionally, in the years since the creation of CR 
packaging, the PPPA, and its underlying regula­
tions (16 CFR 1700–1750), have served as a model 
for many of the other laws, regulations and 
standards employed throughout the world1 (See 
Table 1 for signiﬁcant historical events associated 
with CR packaging and Table S1 for a summary 
of current CR protocols from around the world). 
aThe complete panel name was the 'Medical Advisory Panel 
on Accidental Ingestion and Misuse of Salicylate Prepara­
tions by Children.' 
During the ﬁrst 25 years of US regulation 
(1970–1995), package designers were so focused 
on protecting children from poisoning that they 
frequently forgot to account for the convenience 
of the person needing the medication. The eﬀect 
was the exclusion of many seniors and people 
with disabilities. This was largely because of the 
fact that the CPSC protocol for testing CR 
packages for 'senior friendliness' speciﬁed that 
adults aged 18–45 served as subjects for the 
adult portion of the test. 
In actual usage situations, consumers older 
than 45 had diﬃculties with CR packages, and 
frequently circumvented child-resistant features. 
Many publications from this era, document the 
diﬃculties of consumers.5–17 
By the early 1990s, the CPSC recognized the 
need to design a new test protocol in order to 
facilitate CR package designs that could be used 
more eﬀectively by consumers. As a result, on 
July 21, 1995 the CPSC published a ﬁnal rule 
that revised the senior-friendly portion of the 
test entitled, 'Requirements for the Special 
Packaging of Household Substances; Final 
Rule.'18 Products packaged on or after July 21, 
1998 had to comply with the new adult testing 
requirements (see Fig. 1). 
Because the US protocol was the ﬁrst of its 
kind, it has served as the basis for numerous other 
protocols (see Table S1). This fact is referenced in 
the commonly adopted global standard, ISO 
8317:2004, 'Child-Resistant Packaging – 
Requirements and Testing Procedures for 
Reclosable Packages.' The ISO document indi­
cates, 'A number of other countries have intro­
duced standard test methods based on similar 
principles [to the US protocol]. There are now 
around the world various types of packaging, 
which are recognized as child-resistant, based on 
the test of the nature described.' (ISO 8317, 2004). 
The current test protocol for ensuring 
senior friendly ⁄child resistant packaging 
As a result of the 1995 revision, the current 
protocol employs 100 adults between the ages of 
50 and 70 who do not have 'obvious or overt 
physical or mental disabilities.'18 Figure 1 
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Table 1 Historical events in legislation and regulation of child resistant closures for drug packaging
 
Year Event 
1943 Flavoured aspirin is introduced 
Mid-late 40s Awareness of accidental ingestion builds 
1953 First Poison Control Center is established 
It serves as a central source of information on ingredients, toxicity, expected symptoms and recommen­
dations for treatment 
1957 National Clearinghouse for Poison Control Centers established 
Coordinated efforts of local poison control, gather statistics, and provide diagnostic and therapeutic 
information 
1957 FDA sponsors a meeting of the Medical Advisory Panel 
Discussed accidental ingestion and misuse of salicylate preparations by children 
1957 Efforts to develop safety closures are recommended. 
The drug industry voluntarily complies with recommendations to reduce the strength of children's aspirin 
and to limit the number of tablets in containers to 36. 
1959 Article published in JAMA recommends the use of safety closures [4] 
1961 National Poison Prevention Week established 
Public Law 87–319 designated the third week of March as Poison Prevention week. (ﬁrst observation 1962) 
1966 US House of Representatives Hearings 
Established a joint committee of industrial, professional, and governmental people to develop a meth­
odology. 
1970 Poison Prevention Packaging Act (PPPA) 
Congress deems that legislation was necessary to secure the beneﬁts of CR containers to all consumers. 
1972 Consumer Product Safety Act 
Public Law 92–573 transfers the duties of the PPPA and others to the Consumer Products Safety Com­
mission (effective Spring, 1973) 
1974 National Research Act 
Creates the National Commission for the Protection of Human Subjects of Biomedical and Behavioural 
Research, which, in turn, publishes 'The Belmont Report' 
1990 Proposed rule to change the protocol methodology 
1998 Final rule 
It applies to products packaged on or after July 21, 1998. At least 90% of  'normal' adults (50–70) must be 
able to open the package twice within allotted test periods. At least 80% of children unable to open during 
speciﬁed test. 
depicts the distribution of gender and age of the 
adult test panel and the steps involved in the 
protocol. 
As the protocol begins, test participants are 
screened by testers for 'obvious or overt physical 
or mental disabilities;' participants determined to 
have such disabilities are excluded from testing. 
Participants who are determined to not have 
overt or obvious disabilities then test the pack­
age, individually, in well-lit, distraction free 
areas. The presence of other participants or 
onlookers is not allowed. Each person is pro­
vided 5 min to try to open and close the package 
at test if it is reclosable. If the participant is 
successful, he ⁄ she has to try to open and close a 
second package during a 1-min-period. If the 
person is able to open and close the second 
package during that period, the package gets a 
pass; if not, the data is counted as a failure of the 
CR package for that individual. 
If, in the 5-min period, the person is not able 
to open or close the package, she ⁄he is given a 2­
min screening test (1 min for each screening 
package). This screening determines whether or 
not the participant is able to open packages that 
do NOT have CR features. The screening 
packages are: a plastic snap closure (see Fig. 2a) 
and continuous thread (CT-see Fig. 2b) plastic 
closure that have speciﬁc dimensions and 
requirements for preparation. If the person 
successfully opens and closes both screening 
packages, the participant continues with the 
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The current test protocol for ensuring senior friendly/child resistant packaging 
Figure 1 Diagram of the US CPSC senior-adult test – Reprinted with permission from 'The use of a universal design methodology 
for developing child resistant drug packaging'. 19 
© 2009 The Authors. Journal compilation © 2009 Blackwell Publishing Ltd Health Expectations, 12, pp.430–437 
434 Is the test of senior friendly ⁄ CR packaging ethical?, L Bix et al. 
(a) 
(b) 
Figure 2 Screening Packages (2A-Snap Closure and 2B 
Continuous Thread Closure). 
1-min-period testing the original CR package, 
otherwise the person is eliminated from testing 
and replaced with another participant. See 
Fig. 1 for a schematic of the current adult test, 
as dictated by the protocol. 
A package passes the senior adult test if the 
senior adult use eﬀectiveness (SAUE) is at least 
90%. The SAUE is the percentage of adults who 
both opened the package in the ﬁrst 5-min test 
period and opened and properly closed the 
package in the 1-min test period. 
Despite the fact that the protocol was changed 
to test older adults (aged 50–70 as compared 
with 18–45), studies that have been done since 
the 1995 revision indicate that seniors continue 
to have diﬃculty with CR packages.19–24 This 
problem will continue, and likely grow, as the 
population ages,25,26 lives with increasing levels 
of chronic conditions (see Fig. 3) and engages in 
polypharmacy. 
Ethical considerations with regard to the 
current protocol 
An ethical analysis of the current protocol is 
grounded in four broadly accepted fundamental 
principles of biomedical ethics:27 
1. respect for persons, 
2. beneﬁcence, 
3. non-maleﬁcence, and 
4. justice. 
Respect for persons requires that the auton­
omy of individuals be honoured when decisions 
are made and actions are taken that aﬀect the 
course of their lives; it also restricts us from 
forcing our will and values on others. Beneﬁ­
cence enjoins us to do good, while non-maleﬁ­
cence requires the avoidance of harm. Justice 
requires us to impartially consider the eﬀects of 
our actions on all persons who will be inﬂuenced 
by them. 
The entire process of regulating CR packaging 
has been driven, in large part, by the ethical 
principles of beneﬁcence and non-maleﬁcence. 
• The inadvertent poisoning of children through 
toxic doses of medicine is clearly maleﬁcent, 
and demanded corrective action in the middle 
of the 20th century. 
• Protecting the vulnerable, a population 
including both children and the ill, is beneﬁ­
cent; children are protected through the use of 
CR packaging, and the general population of 
ill persons is protected from undue diﬃculty in 
gaining access to medication through the 
testing process. 
• Some of the restrictions on the testing process 
protect industry from undue burdens (beneﬁ­
cence and non-maleﬁcence) that might result 
from too-stringent requirements in the regu­
lations. For example, the clause in the PPPA 
that CR 'does not mean packaging which all 
such children cannot open or obtain a toxic or 
harmful amount within a reasonable time' 
makes it clear that packaging does not need be 
absolutely impervious to children to pass the 
protocol. 
• Likewise, the stipulation that test subjects 
must be 'normal adults' is also intended to 
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(a) 
(b) 
Figure 3 (a) Percentage of people age 65 and over in selected countries for 2005 and projected 2025. Source: US Census 
Bureau36 (b) Estimated level of disability by age. Source: Agency on Aging37 and US Census Bureau.38 
protect industry from an undue burden in 
designing and manufacturing packaging. 
The obvious success28,29 of the legislated and 
regulated design and use of CR packaging is to 
be celebrated. However, we argue that the 
ethical principle of justice is inadequately 
honoured in the current legislation and regu­
lations because the needs of vulnerable popu­
lations, people with disabilities and consumers 
who experience diﬃculties opening CR pack­
ages, are not being met. 
We acknowledge that a major step toward 
serving vulnerable populations was taken with 
the 1995 revision. Additionally, the law's 
allowance for the use of non-CR prescription 
packages upon request for prescription drugs 
or in a single size for OTCs, aids accessibility. 
But does the current protocol for evaluating 
ease of use go far enough? Research continues 
to indicate diﬃculties associated with the use 
of CR packaging,19–24,30–34 and consumers who 
are forced to choose non-CR systems are not 
aﬀorded the CR protections that they provide. 
It appears to us that the regulations continue 
to be hampered by the regulatory interpretation 
of the 'normal adults' clause in the legislation. 
The vagueness of this stipulation and its neces­
sarily subjective interpretation by test adminis­
trators has unintentionally contributed to the 
continuing diﬃculties reported by many seniors 
in opening drug packages. 
Proposal 
The visual screening for overt or obvious dis­
abilities should be removed from the protocol on 
several grounds. 
1. 'Obvious or overt physical or mental disabi­
lities' is not deﬁned and requires subjective 
judgment that likely varies from one tester to 
another. For example, a potential participant 
using a wheelchair has an obvious physical 
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disability which will lead some testers to 
exclude him or her, but other testers might 
reasonably conclude that this disability is 
irrelevant to the person's ability to open a 
medicine package and include him or her. 
2.	 The subjectivity of the visual screening 
reduces the scientiﬁc rigor of the test to the 
degree that the interpretation can inﬂuence 
test results. 
3.	 The protocol already includes an objective 
screening test designed to determine whether 
a potential participant should be excluded, 
(i.e. the screening packages – see Figs 1 and 
2). This makes the subjective visual screening 
redundant. 
4. Removing the subjective visual screening will 
allow for a greater range of adults, more 
nearly representative of the population, to test 
CR packaging; rigorously adhering to the 
results of the objective screening will protect 
industry from burdensome testing; and the 
rigor of the tests will be increased. 
This change can be made at the regulatory 
level by deﬁning 'normal adult' (the language in 
the legislation) as an individual who can pass the 
objective screening test. Such an interpretation is 
within the spirit of the law because the legis­
lation clearly concerns the ability to open 
medical packages and the objective screening 
test guarantees that only adults with that ability 
serve a test subjects. 
Conclusion 
Although children, 'normal' adults, industry, 
and society as a whole have beneﬁted from the 
implementation of this law, a large and growing 
vulnerable population of seniors and people 
with disabilities, in particular those who share 
living space with children, are disserved by the 
status quo. US Census 2000 enumerated, for the 
ﬁrst time, the number of grandparents that were 
co-residents with grandchildren under the age of 
18. The Census statistics indicated that 5.8 mil­
lion households (or 3.6% of those reporting) 
reported this living arrangement; 35 of these, 
2.4 million indicated themselves to be 'caregiv­
ers' for their grandchild. Undoubtedly, even 
more grandparents are the benefactors of visits 
from children. For all of these households, the 
use of non-CR packaging has the potential to 
put children at risk. 
Through this article, we hope to begin a 
movement to change the test protocols 
throughout the world, to better serve aging 
populations, people with disabilities, and the 
children in their lives. 
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